<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726280</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02930</org_study_id>
    <nct_id>NCT04726280</nct_id>
  </id_info>
  <brief_title>Respiratory Impact of LA Volume After IS Block</brief_title>
  <official_title>Respiratory Impact of Local Anaesthetic Volume for an Interscalene Brachial Plexus Block With an Extrafascial Approach.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eric Albrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that a reduced extrafascial volume of local anesthetic for an&#xD;
      interscalene brachial plexus block is associated with a lower incidence of diaphragmatic&#xD;
      hemiparalysis after an arthroscopic surgery of the shoulder, without any reduction of the&#xD;
      analgesic efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of this study is that a reduced extrafascial volume of local anesthetic for an&#xD;
      interscalene brachial plexus block is associated with a lower incidence of diaphragmatic&#xD;
      hemiparalysis after an arthroscopic surgery of the shoulder, without any reduction of the&#xD;
      analgesic efficacy.&#xD;
&#xD;
      Our prospective randomized controlled trial will include two parallel groups: a group will&#xD;
      receive a volume of 20 mls of ropivacaine 0.75%, while the other group will receive a volume&#xD;
      of 10 mls.&#xD;
&#xD;
      All participants will have a preoperative ultrasound-guided interscalene brachial plexus with&#xD;
      an extrafascial injection of 10 or 20 mls of ropivacaine 0.75%. In both groups, participants&#xD;
      will have an examination of the hemidiaphgragm with the ultrasound, before and 30 min after&#xD;
      the block. The respiratory function will also be assessed with a bedside spirometer before&#xD;
      and after the block, and at 12 and 24 postoperative hours. During surgery all participants&#xD;
      will receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40&#xD;
      milligram kg^2, iv ketorolac 30 milligrams, and iv acetaminophen 1000 milligrams, according&#xD;
      to the current practice in our institution. In the postoperative period, Participants will be&#xD;
      prescribed an IV pca of morphine.&#xD;
&#xD;
      Assignment to one of these two groups will be done according to a computer-generated list of&#xD;
      random numbers, and the sealed envelopes method will be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of hemidiaphragmatic paralysis</measure>
    <time_frame>30 minutes after the interscalene plexus brachial extrafascial injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hemidiaphragmatic paralysis</measure>
    <time_frame>at 2 and 24 postoperative hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Dyspnea</measure>
    <time_frame>in phase 1 recovery and at 12 and 24 postoperative</time_frame>
    <description>Verbal question to the patient if he has dyspnea or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of PONV</measure>
    <time_frame>in phase 1 recovery and at 12 and 24 postoperative</time_frame>
    <description>Verbal question to the patient if he has dyspnea or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Pruritus</measure>
    <time_frame>in phase 1 recovery and at 12 and 24 postoperative hours</time_frame>
    <description>Verbal question to the patient if he has pruritus or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Claude-Bernard-Horner syndrome</measure>
    <time_frame>in phase 1 recovery and at 12 and 24 postoperative hours</time_frame>
    <description>Examination of the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Dysphonia</measure>
    <time_frame>in phase 1 recovery and at 12 and 24 postoperative hours</time_frame>
    <description>Verbal question to the patient if he has dysphonia or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in one second</measure>
    <time_frame>30 minutes after the interscalene plexus brachial extrafascial injection, and at 2, 12 and 24 postoperative hours</time_frame>
    <description>in liters per second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>30 minutes after the interscalene plexus brachial extrafascial injection, and at 2, 12 and 24 postoperative hours</time_frame>
    <description>in liters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak expiratory flow</measure>
    <time_frame>30 minutes after the interscalene plexus brachial extrafascial injection, and at 2, 12 and 24 postoperative hours</time_frame>
    <description>in liters per second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Installation time of sensory block</measure>
    <time_frame>up to 30 minutes after the interscalene plexus brachial extrafascial injection</time_frame>
    <description>in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Installation time of motor block</measure>
    <time_frame>up to 30 minutes after the interscalene plexus brachial extrafascial injection</time_frame>
    <description>in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first dose of postoperative iv morphine</measure>
    <time_frame>up to 24 hours postsurgery</time_frame>
    <description>in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores at rest</measure>
    <time_frame>in phase 1 recovery and at 12 and 24 postoperative hours</time_frame>
    <description>Numeric pain intensity scale. Pain scores range from zero (no pain) to 10 (worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores on movement</measure>
    <time_frame>in phase 1 recovery and at 12 and 24 postoperative hours</time_frame>
    <description>Numeric pain intensity scale. Pain scores range from zero (no pain) to 10 (worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative postoperative iv morphine consumption</measure>
    <time_frame>in phase 1 recovery and at 12 and 24 postoperative hours</time_frame>
    <description>in milligrams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of analgesic block</measure>
    <time_frame>up to 24 hours postsurgery</time_frame>
    <description>in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of motor block</measure>
    <time_frame>up to 24 hours postsurgery</time_frame>
    <description>in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of sensory block</measure>
    <time_frame>up to 24 hours postsurgery</time_frame>
    <description>in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of the participants</measure>
    <time_frame>at 24 postoperative hours</time_frame>
    <description>Numeric satisfaction intensity scale. Satisfactions range from 0 (totally unsatisfied) to 10 (maximal satisfaction).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Arthroscopic Surgery of the Shoulder</condition>
  <condition>Extrafascial Interscalene Plexus Brachial Block</condition>
  <arm_group>
    <arm_group_label>10 ml single-shot injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the 10ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 10 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.&#xD;
Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 ml single-shot injection group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the 20ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 20 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.&#xD;
Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.75% Injectable Solution</intervention_name>
    <description>10 ml extrafascial interscalene brachial plexus block</description>
    <arm_group_label>10 ml single-shot injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.75% Injectable Solution</intervention_name>
    <description>20 ml extrafascial interscalene brachial plexus block</description>
    <arm_group_label>20 ml single-shot injection group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  arthroscopic surgery of the shoulder&#xD;
&#xD;
          -  ASA class 1 to 3&#xD;
&#xD;
          -  age more than 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient refusal or inability to understand and/or sign the inform consent&#xD;
&#xD;
          -  contraindication for perineural block (allergy to local anesthetics, infection of&#xD;
             puncture site, major coagulopathy, sensitive or motor deficiency on the operative side&#xD;
             arm&#xD;
&#xD;
          -  chronic alcool abuse&#xD;
&#xD;
          -  opioid drug abuse or under substitution treatment&#xD;
&#xD;
          -  patients known for allergies to paracetamol, non steroidal anti inflammatory drugs,&#xD;
             dexamethasone, sulfate magnesium, ondansetron, droperidol, and omeprazole;&#xD;
&#xD;
          -  patients under chronic corticotherapy&#xD;
&#xD;
          -  patients known for malignant hyperthermia;&#xD;
&#xD;
          -  patients with chronic kidney failure (Glomerular Filtration Rate &lt; 20 ml/min)&#xD;
&#xD;
          -  patients with severe pulmonary disease&#xD;
&#xD;
          -  patients with history of neck surgery or radiotherapy on the operative side;&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Albrecht</last_name>
    <phone>0041795566341</phone>
    <email>eric.albrecht@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Gonvers</last_name>
    <phone>0041795560194</phone>
    <email>erin.gonvers@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHUV (Centre Hospitalier Universitaire Vaudois)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Albrecht, MD</last_name>
      <phone>+41 79 556 63 41</phone>
      <email>eric.albrecht@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Erin Gonvers</last_name>
      <phone>+41 79 556 01 94</phone>
      <email>erin.gonvers@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Albrecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Eric Albrecht</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

